Alembic Pharmaceuticals received final USFDA approval for its generic Diltiazem Hydrochloride extended-release capsules, designed to treat hypertension. Available in multiple strengths, these capsules ...

Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...

Alembic Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic ...

New microscopic particles could hold key to preventing cardiovascular diseases. Read more at straitstimes.com.

Alembic has a cumulative total of 218 ANDA approvals (191 final approvals and 27 tentative approvals) from USFDA, it added.

Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem ...

Using data from the Coronary Artery Risk Development in Young Adults study, which began in 1983, researchers will gather 35 years of tests and data that follow the participants’ health history from an ...

This is due to the increasing prevalence of CVD and metabolic disorders. The global structural heart devices market, valued ...

Alembic Pharmaceuticals stated that it gained final FDA approval for the Diltiazem Hydrochloride Extended-Release capsules, ...

Thrombosis is a condition that causes blood clots in the vessels. Learn about its types, signs, and treatments.

These capsules will be available in dosages of 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, offering a generic alternative to ...